Ariana Pharma

Silver Sponsor

Ariana Pharma is transforming the way drugs are developed. Key challenges facing clinical

development in early phases is to select optimal patients, indications and endpoints, and

doing so in data-driven mode. This hurdle is even higher considering small number of

patients in early trials characterized by a large number of parameters. Combining advanced

Artificial Intelligence (AI) technology, clinical development, and regulatory expertise, Ariana

optimizes drug development with increased probability of success.

Ariana KEM® explainable Artificial Intelligence (xAI) technology systematically explores any

type of clinical data to produce the most effective biomarker signatures for today’s precision

medicine, optimize clinical endpoints, and identify potential synergistic therapies. Clinical

datasets can be strengthened using Real World Evidence (RWE). Ariana’s multidisciplinary

drug development team leverages the FDA-assessed xAI platform to translate findings into

innovative clinical development plans and regulatory approvals. Our xAI platform is used by

biopharmaceutical and biotech around the world, with a growing number of successful

therapeutic development programs across multiple therapeutic indications.

Founded in 2003 as a spin-off of Pasteur Institute in Paris, the company operates a

subsidiary in the United States. To learn more, visit www.arianapharma.com, follow us on

LinkedIn and Twitter.